Practical Considerations and Specialist Collaboration
Saksena recommends cardiometabolic expertise when prescribing GLP-1 and notes unknown off-target effects require careful management.
Play episode from 36:13
chevron_right
Transcript
chevron_right
Transcript
Episode notes
Dr. Jeanne De Lavallaz and Dr. Ramy Doss discuss the results of the TRANSFORM-AF Trial with expert faculty Dr. Sanjeev Saksena and Dr. Varun Sundaram.
The TRANSFORM-AF trial enrolled 2,510 patients with atrial fibrillation (AF), type 2 diabetes, and obesity across 170 Veterans Affairs hospitals to evaluate the impact of diabetes-dose GLP-1 receptor agonists on AF-related outcomes. Participants were assigned to receive either a GLP-1 receptor agonist, a DPP-IV inhibitor, or a sulfonylurea. The primary composite outcome included AF-related hospitalizations, cardioversions, ablation procedures, and all-cause mortality. Over a median follow-up of 3.2 years, GLP-1 use was associated with a 13% reduction in major AF-related events compared to other therapies. The study population was predominantly male, with a high prevalence of severe obesity (BMI >40 kg/m²) in whom the benefit appeared most pronounced. Notably, the observed benefit occurred despite only modest additional weight loss, suggesting potential non-weight-mediated effects of GLP-1 therapy
Join Us at American Heart Association’s Scientific Sessions 2025!
Don’t miss one of the biggest cardiovascular meetings of the year — AHA Scientific Sessions 2025! 📅 November 7–10, 2025 📍 New Orleans, LA
This is your chance to connect with colleagues, hear the latest cutting-edge science, and be part of the conversation shaping the future of cardiovascular care.
